Skip Navigation
Skip to contents

Ann Coloproctol : Annals of Coloproctology

OPEN ACCESS
SEARCH
Search

Page Path
HOME > Browse Articles
Search
Hyeong-Joon Jeon 1 Article
Adjuvant Chemotherapy Using the FOLFOX Regimen in Colon Cancer
Hyeong-Joon Jeon, Jin-Hee Woo, Hak-Yoon Lee, Ki-Jae Park, Hong-Jo Choi
J Korean Soc Coloproctol. 2011;27(3):140-146.   Published online June 30, 2011
DOI: https://doi.org/10.3393/jksc.2011.27.3.140
  • 5,910 View
  • 46 Download
  • 10 Citations
AbstractAbstract PDF
Purpose

Great progress has been made in the adjuvant treatment of colon cancer. The aim of this study was to evaluate the efficacy of postoperative adjuvant chemotherapy using the FOLFOX regimen in patients with stage III and high-risk stage II colon cancer.

Methods

Eighty-two patients who underwent a potentially curative resection for stage III or high-risk stage II colon cancer were enrolled in this retrospective study. They received FOLFOX4 or modified FOLFOX6. The primary endpoint was disease-free survival.

Results

During the median follow-up of 37 months (range, 21 to 61 months), 14 patients experienced disease relapse. The disease-free survival rate at 3 years was 82.9%: 84.6% for stage II and 82.6% for stage III. At the time of the analysis, 8 patients were dead from recurrence. The probability of overall survival at 5 years was 74.5%: 90% for stage II and 74.6% for stage III. Grade 3 or 4 hematologic adverse events included neutropenia (40.2%), anemia (2.4%), and thrombocytopenia (1.2%). Gastrointestinal toxicities included grade 3 or 4 nausea (4.9%) and stomatitis (2.4%). Peripheral sensory neuropathy was observed in 81.7% of the patients during treatment. Of the 11 patients (13.4%) who had grade 3 peripheral sensory neuropathy during treatment, grade 3 symptoms were persistent in 3 patients with gait disturbance at the time of analysis. No treatment-related deaths were recorded.

Conclusion

Postoperative chemotherapy using the FOLFOX regimen, oxaliplatin in combination with 5-fluorouracil and leucovorin, is effective and tolerable in patients with stage III and high-risk stage II colon cancer.

Citations

Citations to this article as recorded by  
  • Management of metastatic colorectal cancer: consensus in the Gulf Cooperation Council countries
    Bazarbashi Shouki, Alnajjar Abdelsalam, Al Sharm Abdullah, Alshammari Kanan, Al Sherhi Ahmed, Dawoud Emad, Heinemann Volker, Aseafan Mohamed, Chehal Aref, Alghamdi Mohammed, Hamza Dina, Khoury Maroun, Venniyoor Ajit, Mahrous Mervat, Rasul Kakil, Elsamany
    Therapeutic Advances in Medical Oncology.2025;[Epub]     CrossRef
  • Neoadjuvant chemotherapy outcome with taxane-based versus non-taxane protocols in gastric cancer
    Shirin Kianersi, Sina Salari, Hamid Rezvani, Mohammad A. Araskhan, Alireza Shirangi, Mohammad R. Fathi, Mahmoud D. Ghorbi
    Journal of Education and Health Promotion.2023;[Epub]     CrossRef
  • Extending the boundaries of cancer therapeutic complexity with literature text mining
    Danna Niezni, Hillel Taub-Tabib, Yuval Harris, Hagit Sason, Yakir Amrusi, Dana Meron-Azagury, Maytal Avrashami, Shaked Launer-Wachs, Jon Borchardt, M. Kusold, Aryeh Tiktinsky, Tom Hope, Yoav Goldberg, Yosi Shamay
    Artificial Intelligence in Medicine.2023; 145: 102681.     CrossRef
  • Modified Folfox6 as Adjuvant Chemotherapy in Vietnamese Patients With Colorectal Cancer
    T. Quang Nguyen, T. Oanh Bui, P. Thao Tran, V. Thuan Tran, V. Hieu Nguyen, Q. Hoan Chu, T. A. Tuyet Bui, N. Quynh Le, V. Quang Le, V. Tu Dao
    Cancer Control.2019;[Epub]     CrossRef
  • Operative Versus Nonoperative Management of Appendicitis: A Long-Term Cost Effectiveness Analysis
    Lindsay A. Sceats, Seul Ku, Alanna Coughran, Britainy Barnes, Emily Grimm, Matthew Muffly, David A. Spain, Cindy Kin, Douglas K. Owens, Jeremy D. Goldhaber-Fiebert
    MDM Policy & Practice.2019;[Epub]     CrossRef
  • Efficacy and clinical monitoring strategies for immune checkpoint inhibitors and targeted cytokine immunotherapy for locally advanced and metastatic colorectal cancer
    Shelby N. Bess, Gage J. Greening, Timothy J. Muldoon
    Cytokine & Growth Factor Reviews.2019; 49: 1.     CrossRef
  • Association of baseline patient characteristics with adjuvant chemotherapy toxicities in stage III colorectal cancer patients
    Akie Watanabe, Chang Cheng Yang, Winson Y. Cheung
    Medical Oncology.2018;[Epub]     CrossRef
  • Risk Stratification in Patients with Stage II Colon Cancer
    Ramzi Amri, Jonathan England, Liliana G. Bordeianou, David L. Berger
    Annals of Surgical Oncology.2016; 23(12): 3907.     CrossRef
  • Anti-Colorectal Cancer Chemotherapy-Induced Diarrhoea: Current Treatments and Side-Effects
    Rachel M. McQuade, Joel C. Bornstein, Kulmira Nurgali
    International Journal of Clinical Medicine.2014; 05(07): 393.     CrossRef
  • Multiple Cancers in a Patient with Systemic Sclerosis and Aggravated Interstitial Lung Disease by Chemotherapy
    Chan Kwon Park, Seok Jong Lee, Hyung Jun Cho, Kyeong Soo Lee, Sung Jun Kim, Gu Min Cho, Ha Ni Lee
    Tuberculosis and Respiratory Diseases.2013; 75(3): 111.     CrossRef

Ann Coloproctol : Annals of Coloproctology Twitter Facebook
TOP